Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

The fund is sponsored by Vanguard. It has amassed assets over $17.46 billion, making it one of the largest ETFs attempting to match the performance of the Healthcare - Broad segment of the equity ...

Many Americans support prohibiting commercials for prescription drugs on television. But enacting that ban could be ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.

Dividend-screened portfolios of various kinds have failed to keep up with the broad US stock market over the past 10 years, ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...